[Form 4] RELMADA THERAPEUTICS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Relmada Therapeutics (RLMD) filed a Form 4 showing an insider purchase. The company’s Chief Financial Officer, Maged Shenouda, purchased 500,000 shares of common stock on 11/05/2025 at a price of $2.2 per share, coded “P” for purchase.

Following the transaction, beneficial ownership stood at 788,335 shares, reported as direct ownership. The filing reflects a personal share acquisition by a senior officer and updates the executive’s current holdings.

Insights

Equity Governance Analyst

CFO reported buying 500,000 RLMD shares at $2.2, raising direct holdings to 788,335 on 11/05/2025.

Form 4 discloses a direct open-market purchase by the **Chief Financial Officer** of **RELMADA THERAPEUTICS, INC.**. The transaction code is “P” (purchase). The executive acquired **500,000** shares of common stock at an average price of $2.2 on 11/05/2025, resulting in **788,335** shares beneficially owned after the transaction, held **directly**.

What it means: a senior officer increased equity exposure and ownership concentration. This action does not create dilution and reflects a change in insider ownership structure. No derivative securities activity was reported in Table II. The filing does not indicate use of a Rule 10b5‑1 trading plan.

Why it matters: insider purchases are factual shifts in alignment and commitment because personal capital is deployed. Materiality depends on total shares outstanding, which is not provided here. Items to watch include any subsequent Form 4s by this or other insiders, and whether additional purchases or sales occur after 11/05/2025. The next relevant checkpoints are future insider transaction filings and the company’s upcoming periodic reports.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shenouda Maged

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC.

2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)

CORAL GABLES FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2025		P		500,000	A	$2.2	788,335	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Maged Shenouda	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RLMD disclose in this Form 4?

A CFO purchase of 500,000 shares on 11/05/2025 at $2.2 per share, coded “P” for purchase.

Who is the reporting person in RLMD’s Form 4?

The reporting person is Maged Shenouda, the company’s Chief Financial Officer.

How many RLMD shares does the CFO own after the trade?

Beneficial ownership after the transaction is 788,335 shares, held directly.

What was the transaction code and price per share?

Transaction code P (purchase) at a price of $2.2 per share.

When did the RLMD insider transaction occur?

The transaction date was 11/05/2025.

What type of security was involved?

The transaction involved common stock of Relmada Therapeutics, Inc.

Is the ownership direct or indirect after the transaction?

The Form 4 reports direct ownership after the transaction.